S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

AnaptysBio Stock Forecast, Price & News

+1.34 (+4.76 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $29.47
50-Day Range
MA: $28.06
52-Week Range
Now: $29.47
Volume322,885 shs
Average Volume423,539 shs
Market Capitalization$806.48 million
P/E RatioN/A
Dividend YieldN/A
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor for generalized pustular psoriasis and palmoplantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation. AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd.; collaboration with Celgene Corporation; and immuno-oncology collaboration agreement with GlaxoSmithKline plc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California.
AnaptysBio logo


Why AnaptysBio Was a Stock Market Star on Friday
February 26, 2021 |  finance.yahoo.com
Why AnaptysBio Fell by as Much as 10% Today
February 23, 2021 |  finance.yahoo.com
Sensex, Nifty Resume Upward March - Nasdaq
February 12, 2021 |  nasdaq.com
Nasdaq 100 Movers: CERN, KHC - Nasdaq
February 12, 2021 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ANAB
Year FoundedN/A



Sales & Book Value

Annual Sales$8 million
Book Value$14.93 per share


Net Income$-97,340,000.00


Market Cap$806.48 million
Next Earnings Date5/5/2021 (Estimated)


Overall MarketRank

1.15 out of 5 stars

Medical Sector

918th out of 1,968 stocks

Pharmaceutical Preparations Industry

439th out of 771 stocks

Analyst Opinion: 1.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
+1.34 (+4.76 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ANAB News and Ratings via Email

Sign-up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

AnaptysBio (NASDAQ:ANAB) Frequently Asked Questions

Is AnaptysBio a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AnaptysBio stock.
View analyst ratings for AnaptysBio
or view top-rated stocks.

What stocks does MarketBeat like better than AnaptysBio?

Wall Street analysts have given AnaptysBio a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AnaptysBio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is AnaptysBio's next earnings date?

AnaptysBio is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for AnaptysBio

How were AnaptysBio's earnings last quarter?

AnaptysBio, Inc. (NASDAQ:ANAB) released its quarterly earnings results on Thursday, February, 25th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.94 by $0.74.
View AnaptysBio's earnings history

How has AnaptysBio's stock been impacted by Coronavirus?

AnaptysBio's stock was trading at $15.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ANAB shares have increased by 93.5% and is now trading at $29.47.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ANAB?

5 analysts have issued twelve-month price targets for AnaptysBio's stock. Their forecasts range from $16.00 to $40.00. On average, they expect AnaptysBio's share price to reach $28.50 in the next twelve months. This suggests that the stock has a possible downside of 3.3%.
View analysts' price targets for AnaptysBio
or view top-rated stocks among Wall Street analysts.

Who are AnaptysBio's key executives?

AnaptysBio's management team includes the following people:
  • Mr. Hamza Suria, Pres, CEO & Director (Age 45, Pay $573.54k)
  • Mr. Eric J. Loumeau, COO & Gen. Counsel (Age 58, Pay $480.76k)
  • Mr. Dennis M. Mulroy, Chief Financial Officer (Age 66)
  • Ms. Beth Mueller, Sr. VP of HR
  • Dr. Margaret Marino, Sr. VP of Project Management
  • Dr. Paul F. Lizzul, Chief Medical Officer (Age 46)
  • Mr. David McKeon, VP & Controller (Age 49)

Who are some of AnaptysBio's key competitors?

What other stocks do shareholders of AnaptysBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include bluebird bio (BLUE), ImmunoGen (IMGN), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Amarin (AMRN), Editas Medicine (EDIT), Illumina (ILMN), Clovis Oncology (CLVS), Twilio (TWLO) and AbbVie (ABBV).

When did AnaptysBio IPO?

(ANAB) raised $60 million in an IPO on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is AnaptysBio's stock symbol?

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

Who are AnaptysBio's major shareholders?

AnaptysBio's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.98%), Federated Hermes Inc. (4.82%), Frazier Management LLC (3.29%), Dimensional Fund Advisors LP (2.14%), Baker BROS. Advisors LP (1.56%) and Price T Rowe Associates Inc. MD (1.22%). Company insiders that own AnaptysBio stock include Ecor1 Capital, Llc, Eric J Loumeau, Hamza Suria and Marco Londei.
View institutional ownership trends for AnaptysBio

Which major investors are selling AnaptysBio stock?

ANAB stock was sold by a variety of institutional investors in the last quarter, including Frazier Management LLC, Federated Hermes Inc., Baker BROS. Advisors LP, Nuveen Asset Management LLC, Voloridge Investment Management LLC, BlackRock Inc., Russell Investments Group Ltd., and Northern Trust Corp.
View insider buying and selling activity for AnaptysBio
or view top insider-selling stocks.

Which major investors are buying AnaptysBio stock?

ANAB stock was purchased by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Renaissance Technologies LLC, JPMorgan Chase & Co., Hamilton Lane Advisors LLC, Wells Fargo & Company MN, ClariVest Asset Management LLC, Engineers Gate Manager LP, and QS Investors LLC.
View insider buying and selling activity for AnaptysBio
or or view top insider-buying stocks.

How do I buy shares of AnaptysBio?

Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AnaptysBio's stock price today?

One share of ANAB stock can currently be purchased for approximately $29.47.

How much money does AnaptysBio make?

AnaptysBio has a market capitalization of $806.48 million and generates $8 million in revenue each year. The biotechnology company earns $-97,340,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis.

How many employees does AnaptysBio have?

AnaptysBio employs 89 workers across the globe.

What is AnaptysBio's official website?

The official website for AnaptysBio is www.anaptysbio.com.

Where are AnaptysBio's headquarters?

AnaptysBio is headquartered at 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121.

How can I contact AnaptysBio?

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-362-6295 or via email at [email protected]

This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.